NESTLÉ HEALTH SCIENCE EXPANDS ITS DYSPHAGIA OFFERING
Investment in company Phagenesis to address swallowing difficulties experienced by stroke patients
Epalinges, Switzerland, 1 September 2016 - Nestlé Health Science is entering into a staged, milestone-based acquisition of Phagenesis Ltd, a UK-based company developing Phagenyx®, an innovative pharyngeal electrical stimulation device to treat dysphagia (swallowing difficulty). The condition is commonly experienced by post stroke patients, but also the elderly and those undergoing post mechanical ventilation in intensive care units (ICU). Phagenyx® is designed to restore the neurological control of swallowing.
>Press Release Nestlé Health Science